Survey on the Initiation of Aripiprazole Once-Monthly via a Two-Injection Start in Adult Patients with Schizophrenia: Experience of European Healthcare Professionals.
Andrea Fagiolini, Karolina Leopold, Sofia Pappa, William J Cottam, Joe Hickey, Olivia Rogerson, Murat Yildirim, Clodagh Beckham
{"title":"Survey on the Initiation of Aripiprazole Once-Monthly via a Two-Injection Start in Adult Patients with Schizophrenia: Experience of European Healthcare Professionals.","authors":"Andrea Fagiolini, Karolina Leopold, Sofia Pappa, William J Cottam, Joe Hickey, Olivia Rogerson, Murat Yildirim, Clodagh Beckham","doi":"10.1007/s12325-025-03130-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable (LAI) for the maintenance treatment of adults with schizophrenia. The AOM 400 two-injection start initiation regimen (AOM 400-TIS) is an alternative to treatment initiation with one injection of AOM 400 plus 14 days of oral aripiprazole supplementation. This survey investigated the real-world experiences of European healthcare professionals (HCPs) with AOM 400-TIS.</p><p><strong>Methods: </strong>Physicians and nurses in Germany, Italy, and the United Kingdom who had prescribed and/or administered AOM 400-TIS ≥ 3 times to patients with schizophrenia were invited to participate in an online survey. The primary objective was to investigate HCPs' experiences and satisfaction with AOM 400-TIS. Descriptive analysis was performed on data collected between 1 February and 21 March 2024.</p><p><strong>Results: </strong>Data from 94 HCPs were analysed. Most were psychiatrists (62.8%) or psychiatric nurses (29.8%) who worked in specialist mental health clinics/centres (59.6%) or hospitals (inpatient, 36.2%; outpatient, 23.4%). Median duration in clinical practice was 21.0 years. Common reasons for initiating AOM 400-TIS were poor adherence (85.1%), relapse (59.6%), and high hospitalisation rates (48.9%). Common prescribing goals for AOM 400-TIS included improving adherence (70.2%), preventing relapses (69.1%), and improving patient quality of life (62.8%). Barriers to AOM 400-TIS were patients not wanting two injections (66.0%), tolerability concerns (30.9%), and safety concerns regarding administration of a high dose on a single day (28.7%). Key factors influencing prescription of AOM 400-TIS were prior treatment adherence (55.3%) and efficacy (48.9%). Most HCPs agreed/strongly agreed that AOM 400-TIS was easy to administer (79.8%) and had a similar safety/tolerability profile to the one-injection start regimen (69.1%), with the majority satisfied with patient outcomes with AOM 400-TIS (84.0%).</p><p><strong>Conclusions: </strong>European HCPs reported that AOM 400-TIS was easy to administer, well tolerated, and improved treatment outcomes. Barriers to its use included patient reluctance and perceived safety concerns.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-025-03130-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable (LAI) for the maintenance treatment of adults with schizophrenia. The AOM 400 two-injection start initiation regimen (AOM 400-TIS) is an alternative to treatment initiation with one injection of AOM 400 plus 14 days of oral aripiprazole supplementation. This survey investigated the real-world experiences of European healthcare professionals (HCPs) with AOM 400-TIS.
Methods: Physicians and nurses in Germany, Italy, and the United Kingdom who had prescribed and/or administered AOM 400-TIS ≥ 3 times to patients with schizophrenia were invited to participate in an online survey. The primary objective was to investigate HCPs' experiences and satisfaction with AOM 400-TIS. Descriptive analysis was performed on data collected between 1 February and 21 March 2024.
Results: Data from 94 HCPs were analysed. Most were psychiatrists (62.8%) or psychiatric nurses (29.8%) who worked in specialist mental health clinics/centres (59.6%) or hospitals (inpatient, 36.2%; outpatient, 23.4%). Median duration in clinical practice was 21.0 years. Common reasons for initiating AOM 400-TIS were poor adherence (85.1%), relapse (59.6%), and high hospitalisation rates (48.9%). Common prescribing goals for AOM 400-TIS included improving adherence (70.2%), preventing relapses (69.1%), and improving patient quality of life (62.8%). Barriers to AOM 400-TIS were patients not wanting two injections (66.0%), tolerability concerns (30.9%), and safety concerns regarding administration of a high dose on a single day (28.7%). Key factors influencing prescription of AOM 400-TIS were prior treatment adherence (55.3%) and efficacy (48.9%). Most HCPs agreed/strongly agreed that AOM 400-TIS was easy to administer (79.8%) and had a similar safety/tolerability profile to the one-injection start regimen (69.1%), with the majority satisfied with patient outcomes with AOM 400-TIS (84.0%).
Conclusions: European HCPs reported that AOM 400-TIS was easy to administer, well tolerated, and improved treatment outcomes. Barriers to its use included patient reluctance and perceived safety concerns.
期刊介绍：
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
